Literature DB >> 1545130

Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection.

E Fikrig1, S W Barthold, D H Persing, X Sun, F S Kantor, R A Flavell.   

Abstract

Mice vaccinated with outer surface protein A (OspA) from Borrelia burgdorferi strain N40 are protected from challenge with an intradermal syringe inoculum of B. burgdorferi strains N40, B31, and CD16. Vaccination experiments were done to determine if protection extended to strains 297 and 25015. We now show that OspA-N40 immunized mice are protected against challenge with strain 297, isolated from the cerebrospinal fluid of a patient with neuroborreliosis, but not against challenge with strain 25015, isolated from a tick in Millbrook, NY. The OspA gene from strain 25015 was therefore cloned and sequenced. The deduced OspA-25015 protein sequence differs from OspA-N40 at 40 of 273 amino acids. Furthermore, mice vaccinated with rOspA-25015 are protected from challenge with strain 25015 but not against strain N40. The results extend the usefulness of OspA as a vaccine candidate, but indicate that OspA can vary among strains of B. burgdorferi and that vaccination of mice with OspA-N40 does not protect against intradermal challenge with an inoculum of 10(4) strain 25015 spirochetes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545130

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Multiple infections of Ixodes scapularis ticks by Borrelia burgdorferi as revealed by single-strand conformation polymorphism analysis.

Authors:  D S Guttman; P W Wang; I N Wang; E M Bosler; B J Luft; D E Dykhuizen
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Specificity of infection-induced immunity among Borrelia burgdorferi sensu lato species.

Authors:  S W Barthold
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Efficacy of an OspA vaccine preparation for prevention of Lyme disease in New York State.

Authors:  G P Wormser; J Nowakowski; R B Nadelman; I Schwartz; D McKenna; D Holmgren; M Aguero-Rosenfeld
Journal:  Infection       Date:  1998 Jul-Aug       Impact factor: 3.553

4.  Evasion of protective immunity by Borrelia burgdorferi by truncation of outer surface protein B.

Authors:  E Fikrig; H Tao; F S Kantor; S W Barthold; R A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

5.  A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease.

Authors:  S Feng; S Das; T Lam; R A Flavell; E Fikrig
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Virulent strain associated outer membrane proteins of Borrelia burgdorferi.

Authors:  J T Skare; E S Shang; D M Foley; D R Blanco; C I Champion; T Mirzabekov; Y Sokolov; B L Kagan; J N Miller; M A Lovett
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany.

Authors:  B Wilske; U Busch; H Eiffert; V Fingerle; H W Pfister; D Rössler; V Preac-Mursic
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

8.  Molecular typing of Borrelia burgdorferi sensu lato by PCR-restriction fragment length polymorphism analysis.

Authors:  D Liveris; A Gazumyan; I Schwartz
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Ability of canine Lyme disease vaccine to protect hamsters against infection with several isolates of Borrelia burgdorferi.

Authors:  D A Jobe; S M Callister; L C Lim; S D Lovrich; R F Schell
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

10.  Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes.

Authors:  R Wallich; C Helmes; U E Schaible; Y Lobet; S E Moter; M D Kramer; M M Simon
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.